InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 -0.001 (-11.11%)+
Announcement
Release
4 Mar 2026 8:29AM
Price at Release
$0.005
Full Release
download
Summary
AdAlta Limited has expanded its clinical advisory board through its subsidiary, AdCella Pty Ltd, to bolster its Phase 1 trial design expertise for BZDS1901, a CAR-T cell therapy targeting mesothelioma and other solid cancers. This expansion includes the appointments of Nick Pavlakis and Mark Shackleton, who bring expertise in oncology and immunology. BZDS1901, notable for being the first CAR-T product for mesothelioma, aims to address the immune suppression challenges in tumors. Additionally, AdCella’s 'East to West' strategy seeks to harness Asian innovations in T cell therapies, aligning them with Australia's clinical ecosystem. The company is positioning itself to lead in the rapidly growing cellular immunotherapy market, projected to reach US$20.3 billion by 2028.
Key Points
  • AdAlta Limited, listed on ASX as 1AD, is expanding its clinical advisory board through its subsidiary AdCella Pty Ltd.
  • The advisory board aims to strengthen its expertise in clinical oncology, mesothelioma, solid cancer CAR-T cell therapies, haematology, and immunology.
  • Nick Pavlakis and Mark Shackleton were appointed to the board to advise on clinical development and Phase 1 trial design of BZDS1901, a mesothelin-targeted CAR-T cell therapy.
  • BZDS1901 is the first CAR-T product for mesothelioma, secreting its own immune checkpoint inhibitor to overcome tumor immune suppression.
  • The clinical advisory board will support the Australian clinical program for BZDS1901 and ongoing trials in China.
  • AdCella is utilizing an 'East to West' strategy to integrate T cell therapy development from Asia with Australia’s clinical and manufacturing capabilities.
  • The cellular immunotherapy market is projected to grow significantly, with AdCella aiming to be a leader in this field.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.